CareLit · DOI-Nachweis · Pneumologie
Effect of Pirfenidone on Treatment-emergent (TE) All-cause Mortality (ACM) in Patients with Idiopathic Pulmonary Fibrosis (IPF): Pooled Data Analysis from ASCEND and CAPACITY
DOI 10.1055/s-0036-1572066
Bibliografische Angaben
Nachweis in CareLit
Autor:innenU Costabel, SD Nathan, C Albera, WZ Bradford, EA Fagan, I Glaspole, MK Glassberg, D Kardatzke, TE King, KU Kirchgaessler, L Lancaster, DJ Lederer, CA Pereira, JJ Swigris, D Valeyre, PW Noble
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Pooled analysis of the ASCEND and CAPACITY studies showed a significant reduction in the risk of ACM over 52 weeks in patients with IPF treated with pirfenidone compared with placebo, and a nonsignificant trend favoring pirfenidone over the entire study period (up to week 120). Objective: To evaluate TE ACM over the full duration of observation in the pooled population from ASCEND and CAPACITY. Methods:…
Zitieren
Zitierempfehlung
U Costabel, SD Nathan, C Albera, WZ Bradford, EA Fagan, I Glaspole, MK Glassberg, D Kardatzke, TE King, KU Kirchgaessler, L Lancaster, DJ Lederer, CA Pereira, JJ Swigris, D Valeyre, PW Noble (2016) Effect of Pirfenidone on Treatment-emergent (TE) All-cause Mortality (ACM) in Patients with Idiopathic Pulmonary Fibrosis (IPF): Pooled Data Analysis from ASCEND and CAPACITY. Pneumologie (02). https://doi.org/10.1055/s-0036-1572066
Mit CareLit weiterarbeiten